SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.03.25 Share Price

Warrant

DE000SW7LB73

Market Closed - Boerse Frankfurt Warrants 20:41:57 28/06/2024 BST
0.71 EUR +1.43% Intraday chart for SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.03.25
Current month+70.73%
1 month+75.00%
Date Price Change
28/06/24 0.7 0.00%
27/06/24 0.7 -12.50%
26/06/24 0.8 0.00%
25/06/24 0.8 +6.67%
24/06/24 0.75 +1.35%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 08:41 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SW7LB7
ISINDE000SW7LB73
Date issued 12/03/2024
Strike 1,150 $
Maturity 21/03/2025 (265 Days)
Parity 100 : 1
Emission price 0.66
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 0.82
Lowest since issue 0.26
Delta0.46x
Omega 6.354
Premium16.7x
Gearing13.73x
Moneyness 0.9139
Difference Strike 98.97 $
Difference Strike %+8.61%
Spread 0.01
Spread %1.39%
Theoretical value 0.7150
Implied Volatility 27.61 %
Total Loss Probability 62.88 %
Intrinsic value 0.000000
Present value 0.7150
Break even 1,226.58 €
Theta-0.02x
Vega0.03x
Rho0.03x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,051 USD
Average target price
1,051 USD
Spread / Average Target
+0.04%
Consensus